Change of Advisor

22^nd Feb 2017

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces the appointment of Nplus1 Singer Advisory LLP ("N+1 Singer") as Nominated Adviser and sole Broker to the Company with immediate effect.

EKF Diagnostics Holdings plc Julian Baines, CEO Richard Evans, Finance Director and COO	00 44 29 2071 0570
N+1 Singer Alex Price / Alex Laughton-Scott	00 44 20 7496 3000
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

LOGISTICS: A total meltdown

EKF globally launches STAT-Site® WB β-ketone and glucose handheld analyzer

EKF obtains CE mark certification alongside CLIA waiver for easy-to-use whole blood analyzer for diabetes care programmes

EKF opens larger facility to increase production of key component for COVID-19 testing regime

EKF’s new facilities in Llandough, Cardiff, for manufacture of PrimeStore^® MTM viral transport media, enabling pathogenic samples to be collected and transported safely and easily in compliance with UN3373 packaging regulations.

EKF fly the extra mile over Christmas

New COVID-SeroKlir SARS-CoV-2 IgG antibody test kit is one of first to detect both the presence and precise levels of COVID-19 neutralizing antibodies

EKF introduces accurate quantitative COVID-19 antibody test kit

New COVID-SeroKlir SARS-CoV-2 IgG antibody test kit is one of first to detect both the presence and precise levels of COVID-19 neutralizing antibodies